Pfizer leaves COVID product forecast unchanged, shares fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Pfizer (PFE) Earnings Growth 'Underappreciated' - Cantor Fitzgerald
July 28, 2022 1:32 PM EDTPfizer (NYSE: PFE) topped estimates when it reported earnings for the second quarter premarket Thursday.
The drugmaker reported a profit of $2.04 per share, $0.33 better than the analyst estimate of $1.71. Revenue for the quarter came in at $27.7 billion versus the consensus estimate of $25.26... More



